| ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets AJ Souers, JD Leverson, ER Boghaert, SL Ackler, ND Catron, J Chen, ... Nature medicine 19 (2), 202-208, 2013 | 3094 | 2013 |
| Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways G Lenz, GW Wright, NCT Emre, H Kohlhammer, SS Dave, RE Davis, ... Proceedings of the National Academy of Sciences 105 (36), 13520-13525, 2008 | 1161 | 2008 |
| Molecular diagnosis of Burkitt's lymphoma SS Dave, K Fu, GW Wright, LT Lam, P Kluin, EJ Boerma, TC Greiner, ... New England Journal of Medicine 354 (23), 2431-2442, 2006 | 1058 | 2006 |
| Oncogenic CARD11 mutations in human diffuse large B cell lymphoma G Lenz, RE Davis, VN Ngo, L Lam, TC George, GW Wright, SS Dave, ... Science 319 (5870), 1676-1679, 2008 | 1045 | 2008 |
| A loss-of-function RNA interference screen for molecular targets in cancer VN Ngo, RE Davis, L Lamy, X Yu, H Zhao, G Lenz, LT Lam, S Dave, ... Nature 441 (7089), 106-110, 2006 | 773 | 2006 |
| Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours LM Lasko, CG Jakob, RP Edalji, W Qiu, D Montgomery, EL Digiammarino, ... Nature 550 (7674), 128-132, 2017 | 607 | 2017 |
| Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol LT Lam, OK Pickeral, AC Peng, A Rosenwald, EM Hurt, JM Giltnane, ... Genome biology 2, 1-11, 2001 | 444 | 2001 |
| Small molecule inhibitors of IκB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling LT Lam, RE Davis, J Pierce, M Hepperle, Y Xu, M Hottelet, Y Nong, ... Clinical cancer research 11 (1), 28-40, 2005 | 438 | 2005 |
| Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-κB pathways in subtypes of diffuse large B-cell lymphoma LT Lam, G Wright, RE Davis, G Lenz, P Farinha, L Dang, JW Chan, ... Blood, The Journal of the American Society of Hematology 111 (7), 3701-3713, 2008 | 411 | 2008 |
| Signatures of the immune response AL Shaffer, A Rosenwald, EM Hurt, JM Giltnane, LT Lam, OK Pickeral, ... Immunity 15 (3), 375-385, 2001 | 407 | 2001 |
| Ribosomal protein S3: a KH domain subunit in NF-κB complexes that mediates selective gene regulation F Wan, DE Anderson, RA Barnitz, A Snow, N Bidere, L Zheng, V Hegde, ... Cell 131 (5), 927-939, 2007 | 405 | 2007 |
| Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer EJ Faivre, KF McDaniel, DH Albert, SR Mantena, JP Plotnik, D Wilcox, ... Nature 578 (7794), 306-310, 2020 | 305 | 2020 |
| A library of gene expression signatures to illuminate normal and pathological lymphoid biology AL Shaffer, G Wright, L Yang, J Powell, V Ngo, L Lamy, LT Lam, RE Davis, ... Immunological reviews 210 (1), 67-85, 2006 | 248 | 2006 |
| Potential mechanisms of resistance to venetoclax and strategies to circumvent it SK Tahir, ML Smith, P Hessler, LR Rapp, KB Idler, CH Park, JD Leverson, ... BMC cancer 17, 1-10, 2017 | 208 | 2017 |
| Mcl-1 is critical for survival in a subgroup of non-small-cell lung cancer cell lines H Zhang, S Guttikonda, L Roberts, T Uziel, D Semizarov, SW Elmore, ... Oncogene 30 (16), 1963-1968, 2011 | 179 | 2011 |
| Loss in MCL-1 function sensitizes non-Hodgkin’s lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199) DC Phillips, Y Xiao, LT Lam, E Litvinovich, L Roberts-Rapp, AJ Souers, ... Blood cancer journal 5 (11), e368-e368, 2015 | 127 | 2015 |
| Suppression of erythroid but not megakaryocytic differentiation of human K562 erythroleukemic cells by notch-1 LT Lam, C Ronchini, J Norton, AJ Capobianco, EH Bresnick Journal of Biological Chemistry 275 (26), 19676-19684, 2000 | 125 | 2000 |
| Analysis of γc-family cytokine target genes: Identification of dual-specificity phosphatase 5 (DUSP5) as a regulator of mitogen-activated protein kinase activity in interleukin … PE Kovanen, A Rosenwald, J Fu, EM Hurt, LT Lam, JM Giltnane, G Wright, ... Journal of Biological Chemistry 278 (7), 5205-5213, 2003 | 120 | 2003 |
| Preclinical characterization of BET family bromodomain inhibitor ABBV-075 suggests combination therapeutic strategies MH Bui, X Lin, DH Albert, L Li, LT Lam, EJ Faivre, SE Warder, X Huang, ... Cancer research 77 (11), 2976-2989, 2017 | 116 | 2017 |
| Compensatory IKKα activation of classical NF-κB signaling during IKKβ inhibition identified by an RNA interference sensitization screen LT Lam, RE Davis, VN Ngo, G Lenz, G Wright, W Xu, H Zhao, X Yu, ... Proceedings of the National Academy of Sciences 105 (52), 20798-20803, 2008 | 99 | 2008 |
